Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.
Xiuning LeSonam PuriMarcelo V NegraoMonique B NilssonJacqulyne RobichauxTheresa BoyleJ Kevin HicksKatherine L LovingerEmily RoartyWaree RinsurongkawongMing TangHuiying SunYasir ElaminLara C LacerdaJeff LewisJack A RothStephen G SwisherJ Jack LeeWilliam N WilliamBonnie S GlissonJianjun ZhangVassiliki A PapadimitrakopoulouJhanelle E GrayJohn Victor HeymachPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients.See related commentary by Devarakonda and Govindan, p. 6112.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- brain metastases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- radiation therapy
- peritoneal dialysis
- stem cells
- gene expression
- dna methylation
- mesenchymal stem cells
- single cell
- patient reported outcomes
- radiation induced
- bone marrow
- wild type